BC
CLSD

Barnett & Company’s Clearside Biomedical CLSD Stock Holding History

Barnett & Company’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-273
Closed -$7K – 306
2020
Q1 		$7K Sell
273
-60
-18% -$2.22K 0.01% 266
2019
Q4 		$15K Buy
+333
New +$7K 0.01% 266

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Barnett & Company's CLSD Position: Q2 2020 in Review

Barnett & Company sold out of Clearside Biomedical (CLSD) in Q2 2020, closing a stake of 273 shares — an estimated $7K sold.

Barnett & Company first reported a position in CLSD in Q4 2019 and held it in 2 quarters. The position peaked at $15K in Q4 2019. 45 funds tracked by Wall St. Rank hold CLSD as of Q2 2020.

  • Barnett & Company reported no remaining Clearside Biomedical position as of Q2 2020 after selling out during the quarter.
  • Barnett & Company sold 273 Clearside Biomedical shares in Q2 2020, an estimated $7K.
  • Barnett & Company first reported a position in Clearside Biomedical in Q4 2019 and held it in 2 quarters.
  • Barnett & Company's Clearside Biomedical position peaked at $15K in Q4 2019.
  • 45 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2020.

Based on Barnett & Company's 13F filing for Q2 2020, filed 22 Jul 2020.